Greg Chow, M.B.A., has served as the Chief Financial Officer of Sutro since June 2025, bringing more than 25 years of experience across corporate finance, capital markets, drug development operations, and business development.
Prior to joining Sutro, Greg served as Chief Financial Officer and Chief Business Officer at NodThera, and previously held Chief Financial Officer roles at Freenome Holdings, Inc., Frontier Medicines Corp., and Aptose Biosciences, Inc. (Nasdaq: APTO). Earlier in his career, Greg spent fourteen years in investment banking, including leadership roles as Managing Director and Director of Private Placements at Wedbush Securities, and senior roles at RBC Capital Markets and Wells Fargo Securities.
Greg holds an M.B.A. in Finance from The Wharton School at the University of Pennsylvania and a B.A. in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara. Greg is also a Certified Public Accountant (inactive) in the State of California.
What is Gregory K. Chow's net worth?
The estimated net worth of Gregory K. Chow is at least $22.24 thousand as of October 15th, 2025. Mr. Chow owns 1,975 shares of Sutro Biopharma stock worth more than $22,239 as of October 19th. This net worth approximation does not reflect any other assets that Mr. Chow may own. Learn More about Gregory K. Chow's net worth.
How do I contact Gregory K. Chow?
Has Gregory K. Chow been buying or selling shares of Sutro Biopharma?
Gregory K. Chow has not been actively trading shares of Sutro Biopharma within the last three months. Most recently, on Wednesday, October 15th, Gregory K. Chow bought 1,975 shares of Sutro Biopharma stock. The stock was acquired at an average cost of $8.10 per share, with a total value of $15,997.50. Following the completion of the transaction, the chief financial officer now directly owns 1,975 shares of the company's stock, valued at $15,997.50. Learn More on Gregory K. Chow's trading history.
Who are Sutro Biopharma's active insiders?
